Biological Therapies in Cancer Treatment to Reach $66 Billion in 2019; Biosimilars Proving to be a Major Driving Factor

Biological Therapies in Cancer Treatment to Reach $66 Billion in 2019; Biosimilars Proving to be a Major Driving Factor
Wellesley, Mass. (PRWEB) March 24, 2015 Wellesley, Mass., March 24, 2015 – BCC Research (http://www.bccresearch.com) reveals in its new report on biologic cancer treatment that access and affordability of cancer treatment options in various countries, along with a rise in the number of cancer incidences due to better diagnostic approaches, will stimulate growth in the ...

Biological Therapies in Cancer Treatment to Reach $66 Billion in 2019; Biosimilars Proving to be a Major Driving Factor

Biological Therapies in Cancer Treatment to Reach $66 Billion in 2019; Biosimilars Proving to be a Major Driving Factor
Wellesley, Mass. (PRWEB) March 24, 2015 Wellesley, Mass., March 24, 2015 – BCC Research (http://www.bccresearch.com) reveals in its new report on biologic cancer treatment that access and affordability of cancer treatment options in various countries, along with a rise in the number of cancer incidences due to better diagnostic approaches, will stimulate growth in the ...

Atlantic Information Services Webinar to Discuss Payer Strategies for the U.S. Biosimilars Market

Washington, DC (PRWEB) March 20, 2015 Although an approval pathway for biosimilars has been available since the Affordable Care Act passed in 2010, the United States has just this month seen the FDA approve a drug through this process, Sandoz Inc.’s Zarxio. The agency also has been working with other companies that are hoping to ...

DIA And FDLI Collaborate On First Comprehensive Conference On Biosimilars Since The Enactment Of BPCIA

DIA And FDLI Collaborate On First Comprehensive Conference On Biosimilars Since The Enactment Of BPCIA
Horsham, PA (Vocus/PRWEB) March 17, 2011 DIA, in cooperation with the Food and Drug Law Institute (FDLI), will host Future of Biosimilars in the US: Legal, Regulatory, Scientific, Regulatory, Clinical and Payer Issues from May 4-5 in North Bethesda, MD. FDA, industry, lawyers, academics, clinicians, payers, and patients will discuss the challenges and opportunities ...